Multicenter Clinical Study for Reassessment of Prophylactic Approach of Smoking-related Disease by Smoking Addiction Therapeutic Agent and Establishment and Prevalence of Effective Guide for Smoking Cessation

Multicenter Clinical Study for Reassessment of Prophylactic Approach of Smoking-related Disease by Smoking Addiction Therapeutic Agent and Establishment and Prevalence of Effective Guide for Smoking Cessation - NOVA-PGx

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005675

Enrollment

1500

Registered

2011-05-30

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Dependence

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: People aged 20years old over with smoking and smoking history, and able to receive health insurance treatment

Exclusion criteria

Exclusion criteria: 1. aged under 20years 2. patients who are not able to obtain the informed consent 3. patients who are not expected to complete the research with serious disease 4. patients with history of drug allergy 5. patients received the health insurance treatment of smoking addiction within the past year 6. patients with renal disorder contraindicated to both drugs 7. patients recieved the other no-smoking program, such as online no-smoking advise, no-smoking support in industry, and paid no-smoking support or booklet 8. pregnant or nursing women 9. patients determined to inappropriate for the reseach by investigators

Design outcomes

Primary

Measure	Time frame
Relationship between genotype of CYP2A6, drug-metabolizing enzyme involved nicotine dependence, and nicotine dependence	—

Secondary

Measure	Time frame
Relationship between genotype of CYP2A6, drug-metabolizing enzyme involved nicotine dependence, and continuous achievement of smoking cessation or side effect emerged with administration of smoking addiction therapeutic agent	—

Countries

Japan

Contacts

Public ContactMakiko Maeda

Osaka University Graduate School of Pharmaceutical Sciences

makikom@phs.osaka-u.ac.jp06-6879-8163

Outcome results